Internal Medicine, Pulmonary Disease · Pasadena, CA
NPI
1811963762
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
959 E Walnut St, Suite 120
Pasadena, CA, 91106
Phone (626) 795-5118
Groups this clinician bills Medicare through
Medicare paid, 2024
$127K
1,781 services
Medicare patients, 2024
882
Average age 75
Drug cost, 2024
$831K
3,037 prescriptions
Company payments, 2025
$2,519
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Donald M Kroe was code 99213 (office e&m - established), 824 times for 592 patients. In total Donald M Kroe billed 1,781 services in 16 codes, and Medicare paid $127K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-07-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 824 | 592 | $69.05 | $57K |
| 99214 Office E&M - Established | Office | 397 | 264 | $102.88 | $41K |
| 99204 Office E&M - New | Office | 91 | 91 | $131.12 | $12K |
| 94060 Pulmonary Function Testing | Facility | 87 | 87 | $8.20 | $713 |
| 94729 Pulmonary Function Testing | Facility | 84 | 84 | $7.11 | $597 |
| 94727 Pulmonary Function Testing | Facility | 83 | 83 | $9.60 | $797 |
| 95806 Sleep Study | Office | 67 | 66 | $36.01 | $2,413 |
| 99203 Office E&M - New | Office | 48 | 48 | $68.14 | $3,271 |
| 95811 Sleep Study | Office | 37 | 36 | $97.69 | $3,615 |
| 95810 Sleep Study | Office | 24 | 24 | $96.90 | $2,326 |
| 99215 Office E&M - Established | Office | 14 | 12 | $154.71 | $2,166 |
By year: 2022 $123K for 1,689 services; 2023 $106K for 1,499 services; 2024 $127K for 1,781 services.
Medicare prescription drug claims, 2024
In 2024, the drug Donald M Kroe prescribed most often to Medicare patients was Albuterol Sulfate Hfa (Albuterol Sulfate), with 648 prescriptions and refills. In total Donald M Kroe wrote 3,037 Medicare prescriptions that cost $831K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 648 | 786 | 225 | $16K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 183 | 202 | 31 | $123K |
| Prednisone Generic | 165 | 187 | 72 | $468 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 164 | 214 | 37 | $26K |
| Spiriva Respimat Tiotropium Bromide | 164 | 215 | 35 | $106K |
| Zolpidem Tartrate Generic | 132 | 157 | 19 | $922 |
| Breo Ellipta Fluticasone/Vilanterol | 128 | 164 | 29 | $64K |
| Wixela Inhub Fluticasone Propion/Salmeterol | 119 | 195 | 30 | $24K |
| Azithromycin Generic | 114 | 114 | 69 | $391 |
| Montelukast Sodium Generic | 93 | 220 | 25 | $1,038 |
| Incruse Ellipta Umeclidinium Bromide | 69 | 99 | 14 | $32K |
| Atrovent Hfa Ipratropium Bromide | 66 | 86 | 15 | $45K |
| Clonazepam Generic | 65 | 69 | Under 11 | $328 |
| Modafinil Generic | 56 | 62 | Under 11 | $9,496 |
| Spiriva Handihaler Tiotropium Bromide | 52 | 78 | Under 11 | $39K |
Brand drugs: 1,526 claims; generic drugs: 1,511 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Donald M Kroe $2,519 ($2,519 in general payments such as food, travel and fees) from 23 companies. The largest payer was GlaxoSmithKline, LLC. with $423.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 24 | $423 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $307 |
| Harmony Biosciences LLC HRMY | 8 | $269 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $182 |
| Inspire Medical Systems, Inc. INSP | 4 | $172 |
| Axsome Therapeutics, Inc. AXSM | 9 | $170 |
| Verona Pharma, Inc. VRNA | 6 | $161 |
| Insmed, Inc. INSM | 7 | $146 |
| Merck Sharp & Dohme LLC MRK | 4 | $79.99 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $77.29 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.